Open Access

Disseminated and late metastatic disease from nasal pit leiomyosarcoma after radical surgical resection. Case report of a singular presentation of a rare disease

Clinical Sarcoma Research20177:12

https://doi.org/10.1186/s13569-017-0078-2

Received: 5 August 2016

Accepted: 15 February 2017

Published: 6 June 2017

Abstract

Background

Leiomyosarcoma of the head and neck is a rare cancer with high local aggressiveness. Radical surgery and adjuvant treatment offer the best chance for cure, nonetheless 5-years recurrence rate remains high. Despite international guidelines are available for soft tissue sarcomas, no recommendations are specifically endorsed for leiomyosarcoma of the head and neck, due to the rarity of its presentation and consequently scarcity of data on long-term outcome.

Case presentation

A 50-year old woman, operated 10 years before for leiomyosarcoma of the nasal pit and with negative 5-years follow-up, was admitted to our ward for impairment of the hepatic function. Total-body CT scan detected multiple localizations at lungs, kidneys, pancreas, bones, muscles, lymph nodes and thyroid. The pathologic report after lung biopsy confirmed the diagnosis of metastasis from leiomyosarcoma and the patients was scheduled for first line chemo-radiotherapy.

Conclusions

Despite adequate primary treatment, distant and disseminated metastatic disease may be not excluded in leiomyosarcoma of the head and neck.

Keywords

Leiomyosarcoma Nasal pit Metastasis Follow up Pancreas

Background

Soft tissue sarcomas (STS) are malignant tumors of mesenchymal origin, arising in connective tissue and extra-osseous connective tissue and representing about 1% of all adult cancers [1]. A rare histotype is represented by leiomyosarcoma of the head and neck, which accounts less than 0.1% of the tumors of this anatomic region [2]. When arisen in the area of head and neck its typical presentation involves the oral cavity, scalp, paranasal sinuses and jaws [3].

Despite international guidelines are available for staging work-up and therapeutic option of STS [4, 5], due to its uncommon occurrence, leiomyosarcoma of the head is burden by scarcity of data concerning long-term outcome and optimal management. Radical surgical resection associated with adjuvant chemoradiation seems to offer the best chance for cure [6].

Accurate data on long-term outcome are lacking. The largest retrospective series on 130 patients with sarcomas of the head and neck reported a 68% 5-years metastasis free-survival, a local recurrence rate within 5 years of more than 50%. In nearly half of metastatic patients it is observed a concomitant relapse in the primary site, suggesting high local aggressiveness. The classical sites of distant dissemination are liver, bone, brain and skin [7].

This article presents a case of a 50-year old woman with disseminated metachronous metastases of leiomyosarcoma diagnosed 10 years after being operated and treated with radiotherapy for a primary tumor of the nasal pit and with a negative 5-years follow-up.

Case presentation

A 50-year old woman suffering from psoriasis underwent a radical resection of a leiomyosarcoma of the nasal pit in the year 2006 she was subsequently treated with 13.2 Gy/12 fractions of radiotherapy. In the year 2011 she completed a 5-years negative follow up. No cases of soft tissue sarcoma were noticed among her relatives.

In April 2016 the patient was admitted to our surgical ward for the incidental finding of abnormal values of hepatic function laboratory tests: alkaline phosphatase 286 U/L; gamma-glutamyl transferase 621 U/L; bilirubin 0.8 mg/dL; AST 488 U/L; ALT 1248 U/L. Patient history revealed abdominal discomfort in the previous 4 months. For this reason she underwent an abdominal ultrasound that excluded pathological findings. She had no symptoms or signs of pancreatic exocrine or endocrine insufficiency and no weight loss.

After admission, the patient repeated an abdominal ultrasound scan that showed dilation of the intrahepatic bile ducts and a solid hypoechogenic 4 cm mass of the head of the pancreas. She was then submitted to a total-body contrast-enhanced TC-scan with detection of multiple hypodense pancreatic lesions (Fig. 1), bilateral hypodense renal lesions (Fig. 2) and bilateral lung lesions (Fig. 3). Liver and kidney lesions appear hypodense both in venous phase and after contrast enhancement. No malignancy was detected in the brain at CT-scan. The radiologic report was suggestive for primary lung cancer with multiple abdominal metastases. Thus, the patient received a CT-guided core needle lung biopsy for histological characterization.
Fig. 1

Contrast-enhanced CT-scan with detection of multiple hypodense pancreatic lesions

Fig. 2

Contrast-enhanced CT-scan with detection of multiple, hypodense and bilateral kidney lesions

Fig. 3

Bilateral lung metastases at CT-scan

The biopsy (Fig. 4) was constituted of lung parenchyma invaded by a population of fusiform elements with marked nuclear pleomorphism, hyperchromasia and high mitotic activity growing in a fascicular pattern. Immunohistochemistry of the neoplastic elements revealed them to be positive for smooth muscle actin, muscle-specific actin and desmin, and negative for pool cytokeratin markers (AE1–AE3). The immunophenotype of the lesion was thus compatible with metastases from the previous leiomyosarcoma. The histological slides were reviewed in a sarcoma referral center by an expert pathologist, who confirmed the diagnosis.
Fig. 4

Histologic features of the core-needle biopsy. The lesion was constituted of malignant smooth muscle fascicles, as demonstrated by the immunohistochemistry for smooth muscle actin (SMA) and pool cytokeratin (CK, which is shown to have a positive control on the normal lung parenchyma left)

To further explore the maxillary region, a magnetic resonance was prescribed with the evidence of an additional lesion at left supraclavicular lymph nodal region. We completed the oncological staging by a total-body PET scan, which confirmed the multiple metastases at lungs, kidneys and pancreas, multiple high-metabolic intensity signals at bones (left occipital condyle, ribs, vertebrae, and pelvis), muscles (right pectoralis major, left vastus intermedius and left rhomboid) thoracic lymph nodes, and thyroid gland.

The patient was evaluated for oncological treatment at a referral center. She started radiochemotherapy with 6 cycles of anthracycline and dacarbazine, plus single-fraction 8 Gy on selected bone localization. At restaging with total-body enhanced CT-scan and total-body PET-CT scan, partial remission of the disease was observed, according to RECIST criteria [8]. At last clinical follow-up at our Institution (November 2016), the patient was still undergoing single-drug chemotherapy scheme with systemic dacarbazine, showing good quality of life.

Conclusions

Leiomyosarcoma of the head is a very uncommon malignant disease, characterized by high local aggressiveness. Since the incidence of this type of neoplasm is low, all patients should be treated by multidisciplinary team at referral centers.

It has been suggested that radical surgical resection followed by adjuvant chemoradiation or neoadjuvant local radiation with postoperative chemotherapy, may represent the best opportunities for cure, but so far no gold standard treatments and follow-up protocols have been clearly recommended for head and neck leiomyosarcoma [9].

Our patient presented with disseminated metastatic disease. We initially hypothesized that it might origin by a new growth carcinoma. The pathologic report was edited after comparing the lung biopsy with the surgical specimen of the former leiomyosarcoma and in both cases similar morphologic and immunohistochemistry patterns were found. Despite the resection of the former leiomyosarcoma dated 10 years negative follow up, the rarity of the disease and its pathognomonic features at pathology suggested that a relapse of the previous malignancy might be more likely than a new primary tumor.

Metastases from leiomyosarcoma have been commonly described following local recurrence and, in case of primary lesion at head and neck, distant relapse is usually detected in the cervical region or in the lungs [10], while no cases of abdominal metastases have been reported. Beside pulmonary metastases (a common feature of leiomyosarcoma), the patient presented with multiple abdominal metastases in the kidneys and in the pancreas. Both the latter presentations are peculiar because distant localization in the kidney is anecdotal [11] and pancreatic metastases are often solitary and found within a short period of time.

Suh et al. [12] recently reviewed their experience on 13 cases of pancreatic metastases from leiomyosarcoma. The majority of patients had the primary tumor originating from uterus, retroperitoneum or lower extremities and in most of cases a single metastasis was described with a median resection-to-relapse time of 17 months (range 1–77 months). Multiple site metastases or synchronous spread presentation of leiomyosarcoma have been observed, but only in patients with impaired immune function due to radiation therapy, HIV, other neoplasms or in transplant receipts. In those cases, Epstein–Barr virus infection seems to play a key-role in the pathogenesis of the disease [13, 14]. Since our patient did not fulfill the above conditions, a reliable reason for multiple tumor localization remains uncertain. Hematogenous dissemination is a common trait of leiomyosarcoma [8]. Thus, it may be hypothesized that the abdominal presentation may have followed the lung metastasis process, through systemic blood flow, but we did not observe hepatic localization. This remark seems peculiar, if considering the common origin of the pancreatic and liver arterial blood flow from the celiac trunk. The present case was characterized by the late and extensive appearance of the metastatic disease, absence of local recurrence, young age and lack of concomitant immune impairment, suggesting a very high aggressive biologic behavior of the tumor.

Local recurrences have been described up to 15 years after primary resection [7]. Similarly to our observation, Minni et al. reported that three patients, out of a series of four, developed metachronous pancreatic metastases at an interval of 9.2 years after the diagnosis of primary tumor [15]. Nonetheless relapse appears more often in the first 3 years after surgery [16] and recurrence after 5 years remains an uncommon manifestation [17].

In conclusion, despite radical resection, adjuvant chemoradiation and accurate long-term follow-up, distant and disseminated recurrence of the disease may not be excluded in leiomyosarcoma of the head and neck. Since prompt multimodal treatment of metastatic disease may improve overall survival, the suggested 10-years follow-up should be fulfilled. The adequate timing to interrupt surveillance after resection and its cost-effectiveness need further investigation.

Declarations

Authors’ contributions

All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Formal ethics approval was not required owing to the retrospective, observational, and anonymous nature of this case report.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Surgery, School of Medicine and Surgery, San Gerardo Hospital (4° Piano A), University of Milano Bicocca
(2)
Unit of Pathology, School of Medicine and Surgery, San Gerardo Hospital, University of Milano Bicocca

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.View ArticlePubMedGoogle Scholar
  2. Salzer AT. Leiomyosarcoma of head and neck. Houston: Baylor college of medicine; 1993.Google Scholar
  3. Marioni G, et al. Laryngeal leiomyosarcoma. J Laryngol Otol. 2000;114:398–401. doi:https://doi.org/10.1258/0022215001905698.View ArticlePubMedGoogle Scholar
  4. NCCN guidelines. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 1 Sep 2016.
  5. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: eSMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii102–12.View ArticleGoogle Scholar
  6. Yadav J, Bakshi J, Chouhan M, Modi R. Head and neck leiomyosarcoma. Indian J Otolaryngol Head Neck Surg. 2013;65(Suppl 1):1–5.View ArticlePubMedGoogle Scholar
  7. Eeles RA, Fisher C, A’Hern RP, Robinson M, Rhys-Evans P, Henk JM, Archer D, Harmer CL. Head and neck sarcomas: prognostic factors and implications for treatment. Br J Cancer. 1993;68(1):201–7.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Therasse P, Le Cesne A, Van Glabbeke M, Verweij J, Judson I, EORTC Soft Tissue and Bone Sarcoma Group. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer. 2005;41(10):1426–30.View ArticlePubMedGoogle Scholar
  9. Serrano C, George S. Leiomyosarcoma. Hematol Oncol Clin North Am. 2013;27(5):957–74.View ArticlePubMedGoogle Scholar
  10. Schütz A, Smeets R, Driemel O, Hakim SG, Kosmehl H, Hanken H, Kolk A. Primary and secondary leiomyosarcoma of the oral and perioral region—clinicopathological and immuno histochemical analysis of a rare entity with a review of the literature. J Oral Maxillofac Surg. 2013;71(6):1132–42.View ArticlePubMedGoogle Scholar
  11. Demos TC, Schiffer MS, Reynes CJ. Metastatic leiomyosarcoma of the kidney with spontaneous perirenal hemorrhage. Diagn Imaging Clin Med. 1984;53(2):87–90.PubMedGoogle Scholar
  12. Suh CH, Keraliya A, Shinagare AB, Kim KW, Ramaiya NH, Tirumani SH. Multi detector computed tomography features of pancreatic metastases from leiomyosarcoma: experience at a tertiary cancer center. World J Radiol. 2016;8(3):316–21.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Rogatsch H, Bonatti H, Menet A, Larcher C, Feichtinger H, Dirnhofer S. Epstein–Barr virus associated multicentric leiomyosarcoma in an adult patient after heart transplantation: case report and review of the literature. Am J Surg Pathol. 2000;24(4):614–21.View ArticlePubMedGoogle Scholar
  14. Deyrup AT, Lee VK, Hill CE, Cheuk W, Toh HC, Kesavan S, Chan EW, Weiss SW. Epstein–Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol. 2006;30(1):75–82.View ArticlePubMedGoogle Scholar
  15. Minni F, Casadei R, Perenze B, Greco VM, Marrano N, Margiotta A, Marrano D. Pancreatic metastases: observations of three cases and review of the literature. Pancreatology. 2004;4:509–20.View ArticlePubMedGoogle Scholar
  16. Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer. 2014;110(10):2420–6.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Youn P, Milano MT, Constine LS, Travis LB. Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients. Cancer. 2014;120(15):2334–42.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement